NICE Issues Guidance Recommending Translarna for Pediatric DMD
The National Institute for Health and Care Excellence (NICE) has just issued new guidance recommending Translarna (ataluren) for children older than 5 who have Duchenne muscular dystrophy (DMD). The guidance, titled “Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene,” follows the…